Hepalink USA, the wholly owned U.S. subsidiary of Shenzhen Hepalink Pharmaceutical, will acquire the biopharmaceutical contract development manufacturing organization Cytovance® Biologics for $205.68 million cash plus additional contingent payments, Cytovance said today. The deal adds a CDMO to Hepalink’s U.S. portfolio, which includes Scientific Protein Laboratories (SPL), a global supplier of active pharmaceutical ingredients (APIs). […]